MDT

98.76

+1.94%↑

A

146.17

-0.01%↓

VEEV

219.86

-1.14%↓

HQY

89.05

+3.23%↑

NEOG

9.5

+3.26%↑

MDT

98.76

+1.94%↑

A

146.17

-0.01%↓

VEEV

219.86

-1.14%↓

HQY

89.05

+3.23%↑

NEOG

9.5

+3.26%↑

MDT

98.76

+1.94%↑

A

146.17

-0.01%↓

VEEV

219.86

-1.14%↓

HQY

89.05

+3.23%↑

NEOG

9.5

+3.26%↑

MDT

98.76

+1.94%↑

A

146.17

-0.01%↓

VEEV

219.86

-1.14%↓

HQY

89.05

+3.23%↑

NEOG

9.5

+3.26%↑

MDT

98.76

+1.94%↑

A

146.17

-0.01%↓

VEEV

219.86

-1.14%↓

HQY

89.05

+3.23%↑

NEOG

9.5

+3.26%↑

Search

CareDx Inc

Open

SectorGezondheidszorg

20.78 3.38

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

19.94

Max

20.83

Belangrijke statistieken

By Trading Economics

Inkomsten

10M

1.7M

Verkoop

13M

100M

K/W

Sectorgemiddelde

16.07

90.831

Winstmarge

1.674

Werknemers

644

EBITDA

11M

6.8M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-12.49% downside

Dividenden

By Dow Jones

Volgende Winsten

25 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

309M

1.1B

Vorige openingsprijs

17.4

Vorige sluitingsprijs

20.78

Nieuwssentiment

By Acuity

50%

50%

151 / 361 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

CareDx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 jan 2026, 22:41 UTC

Acquisities, Fusies, Overnames

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15 jan 2026, 00:00 UTC

Winsten

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14 jan 2026, 23:47 UTC

Marktinformatie

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14 jan 2026, 23:44 UTC

Marktinformatie

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14 jan 2026, 23:39 UTC

Marktinformatie

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14 jan 2026, 23:32 UTC

Marktinformatie

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14 jan 2026, 22:56 UTC

Acquisities, Fusies, Overnames

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14 jan 2026, 22:53 UTC

Acquisities, Fusies, Overnames

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14 jan 2026, 22:17 UTC

Marktinformatie

Global Equities Roundup: Market Talk

14 jan 2026, 22:17 UTC

Marktinformatie

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14 jan 2026, 22:09 UTC

Winsten

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14 jan 2026, 22:08 UTC

Winsten

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14 jan 2026, 22:08 UTC

Winsten

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14 jan 2026, 21:53 UTC

Acquisities, Fusies, Overnames

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14 jan 2026, 21:53 UTC

Acquisities, Fusies, Overnames

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14 jan 2026, 21:52 UTC

Acquisities, Fusies, Overnames

WuXi XDC Announces Positive Profit Alert for 2025

14 jan 2026, 21:51 UTC

Acquisities, Fusies, Overnames

Citigroup Acting as Financial Advisor to WuXi XDC

14 jan 2026, 21:51 UTC

Acquisities, Fusies, Overnames

WuXi XDC: Aims to Keep Listing Status of BioDlink

14 jan 2026, 21:51 UTC

Acquisities, Fusies, Overnames

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14 jan 2026, 21:50 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

14 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

14 jan 2026, 21:49 UTC

Acquisities, Fusies, Overnames

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14 jan 2026, 21:48 UTC

Acquisities, Fusies, Overnames

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14 jan 2026, 21:48 UTC

Acquisities, Fusies, Overnames

WuXi XDC Makes Cash Offer for BioDlink International

14 jan 2026, 21:13 UTC

Marktinformatie

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14 jan 2026, 20:30 UTC

Marktinformatie
Winsten

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14 jan 2026, 20:13 UTC

Marktinformatie

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14 jan 2026, 20:08 UTC

Marktinformatie

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14 jan 2026, 19:33 UTC

Marktinformatie

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14 jan 2026, 19:06 UTC

Marktinformatie
Winsten

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Peer Vergelijking

Prijswijziging

CareDx Inc Prognose

Koersdoel

By TipRanks

-12.49% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 18 USD  -12.49%

Hoogste 18 USD

Laagste 18 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor CareDx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

4 ratings

1

Buy

3

Hold

0

Sell

Technische score

By Trading Central

14.77 / 18.49Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

151 / 361 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat